Cigarette smoking increases the risk of numerous health problems, including cancer, cardiovascular and pulmonary disorders, making smoking the leading cause of preventable death in the world. Nicotine is primarily responsible for the highly addictive properties of cigarettes. Although the majority of smokers express a desire to quit, few are successful in doing so. Twin and family studies have indicated substantial genetic contributions to smoking behaviors. One major research focus has been to elucidate the specific genes involved; this has been accomplished primarily through genome-wide linkage analyses and candidate gene association studies. Much attention has focused on genes involved in the neurotransmitter pathways for the brain reward system and genes altering nicotine metabolism. This paper reviews the current state of knowledge for genetic factors implicated in smoking behaviors, and examines how genetic variations may affect therapeutic outcomes for drugs used to assist smoking cessation.
Introduction
According to the World Health Organization (WHO), tobacco smoking is responsible for the death of approximately 5 million people each year. 1 In spite of increasingly strict tobacco control policies and the numerous adverse health effects associated with cigarette smoking, approximately 22% of adults in the United States are smokers. 2, 3 Although the majority (B80%) of smokers express a desire to quit smoking, less than 5% are able to do so unaided owing to the highly addictive properties of nicotine, the primary psychoactive substance in tobacco smoke. 4, 5 Currently, US Food and Drug Administration (FDA)-approved pharmacotherapies to aid smoking cessation include nicotine replacement therapies (NRT) and the antidepressant bupropion (Zyban). 6 In general, these drugs increase the risk of quitting by 1.5-2-fold; 7 however, there is large interindividual variability in response and few maintain long-term abstinence. 8, 9 Thus, there is a need to better understand the biological determinants of nicotine dependence (ND) and cessation.
Cigarette smoking is a complex behavior that includes a number of stages such as initiation, experimentation, regular use, dependence, cessation and relapse. 10, 11 Although environmental factors such as the influence of family members, peers and culture undoubtedly affects one's smoking behaviors at these stages, genetics also has a substantial role. Numerous twin, adoption and family studies have been performed and large variations in the estimation of heritability of 'ever' smoking have been reported in ranges of 11-78%. [12] [13] [14] [15] [16] [17] [18] [19] [20] This may be due, at least in part, to the broadness of this phenotype which encompasses those who have only tried cigarettes once to regular heavy smokers. Once smoking is initiated, the heritability for persistence to regular smoking has been estimated at 28-84%, 12, [15] [16] [17] [19] [20] [21] for number of cigarettes smoked at 45-86% [21] [22] [23] [24] [25] [26] and for diagnosed ND at 31-75%. 19, 21, 27 A genetic influence on nicotine withdrawal symptoms and smoking cessation has also been identified with heritability estimated at 26-48 and 50-58%, respectively. [28] [29] [30] Taken together, these studies suggest a substantial genetic contribution to most aspects of smoking. It should be noted that genetic risk factors for different aspects of smoking (such as initiation and persistence) only partially overlap, suggesting some genes will be specific to one smoking phenotype whereas others may influence multiple aspects of smoking. 14, 17, 19, 31 Further, the proportion of genetic versus environmental influences on the different smoking stages vary by gender, 16, 20, [32] [33] [34] with genetics appearing to have a larger role on initiation compared to persistence in women, whereas the opposite is observed in men. 20 While heritability studies can demonstrate a genetic influence in smoking behaviors, advances in our understanding of the human genome have allowed for the localization of specific genes involved. Genome-wide linkage analysis is used to locate areas in the genome with high linkage disequilibrium for a specific phenotype such as ND. The impact of variation in genes found in these loci can then be examined in candidate gene association studies. Candidate gene association studies have focused primarily on targets identified in linkage studies and on genes selected for their biological relevance. Current research has focused mainly on genes involved in neurotransmitter pathways of the brain reward system and nicotine metabolism. It should be noted that like other complex disorders, it is likely that multiple interacting genetic factors underlie ND with each gene contributing a small effect. 21, 35, 36 This review will provide a brief overview of the data from linkage scans and candidate gene association studies, and discuss some of the observed discrepancies in the literature. An examination of how genetic variation may be associated with differential outcomes to nicotine cessation pharmacotherapies will also be described. A better understanding of the genetic influences on the different smoking stages and phenotypes can provide a rationale for prevention strategies, can be used to optimize current treatments and provide novel targets for the development of new treatments.
Genome-wide linkage studies
Genome-wide linkage studies have become more feasible with the availability of denser markers, higher throughput and cost-effective genotyping methods. Particularly with complex polygenetic traits, genome-wide scans are valuable because they can detect genes that might have been overlooked in candidate gene association studies. A wide variety of smoking phenotypes have been investigated (Table 1) , however only two genome-wide scans using direct measures of ND have been published. [37] [38] [39] Some of the loci associated with ND are near genes of known biological relevance, including the m 1 -opioid receptor (OPRM1) on chromosome 6, serotonin receptor 5A on chromosome 7 as well as a 2 -nicotinic acetylcholine receptor (CHRNA2) and a 1A -adrenergic receptor (ADRA1A) on chromosome 8. 39 Loci identified with other smoking phenotypes also contain some biologically interesting candidates, such as a region on chromosome 5q located near the dopamine receptor (D 1 ) gene, which has been reported in several studies. 32, 40, 41 Regions on chromosomes 6, 9 and 11 26, 32, 33, [40] [41] [42] [43] [44] [45] [46] are also promising as several studies have replicated the linkage and these regions contain some potential biologically relevant candidate genes (Table 1) .
Numerous loci have been implicated, but few reached statistical significance and few were replicated in independent studies. A major hurdle in genome scans and candidate gene association studies for complex disease is the presence of genetic heterogeneity and multiple interacting genes each with moderate effect. The size of the genetic effect, the density of the markers, the subject size and composition, the narrowness of the phenotype, the statistical approaches used, and the number of genes involved will alter the likelihood of detecting a significant signal. As such, replication of data from genome-wide linkage scans for smoking phenotypes has been difficult.
Candidate gene association studies
Nicotine is the main psychoactive ingredient in cigarettes, readily crossing the blood-brain barrier and targeting nicotinic acetylcholine receptors (nAChRs). 47, 48 Activation of nAChRs in the ventral tegmental area (VTA) leads to increased dopamine release in the nucleus accumbens and stimulation of the mesolimbic brain reward pathways, 49 a feature common to most drugs of abuse. Smoking is a chronic, relapsing disorder beginning with initiation and progressing to regular smoking. Repeated nicotine administration results in neuronal adaptations, such as upregulation of nAChRs, [50] [51] [52] producing dependence and tolerance such that drug abstinence is accompanied by withdrawal symptoms. 53 To avoid these effects, dependent smokers are known to regulate their nicotine intake in order to maintain levels in the blood and brain. 54 Thus, the majority of candidate association studies have focused on genes in relevant neurotransmitter pathways for drug reward and nicotine metabolism.
Dopaminergic system

Dopamine receptors
The dopaminergic system has received considerable attention because its role in the rewarding properties of nicotine is well established. [55] [56] [57] c DSM-IV dependence was defined as a continuous score across seven ND criteria (tolerance, withdrawal, ever smoked more than meant to, difficulty quitting, great deal of time spent obtaining cigarettes, give up important social or occupational activities in order to smoke, continue smoking despite health problems caused or exacerbated by smoking) or as a categorical measure where at least three of the seven criteria were reported. DSM-IV criteria were based on DSM-based Nicotine Dependence Scale along with other questionnaire items.
229
d Follow-up study using markers of the most positive regions in chromosomes 2, 4, 10, 16, 17, 18 derived from the complete genome scan of the Christchurch, New Zealand samples. e Secondary analyses for the complete genome scan of the Christchurch, New Zealand samples. f When simultaneous linkage analyses were performed for regions with LOD42, the region in chromosome 5 explained most of the variance in age of initiation and the region in chromosome 22 was no longer significant. g In the genome scan for the Australian Twin Registry samples, analyses were extended to incorporate sex differences in smoking phenotypes. The most significant P-value of the two models (accounting for sex differences or assuming equal effects) is provided here. h For reference Bergen et al., 230 only loci with P-values demonstrating at least 'suggestive' linkage (Po0.00074) according to Lander and Kruglyak 231 are listed. Six loci in chromosomes 1, 2, 6 and 15 had evidence for linkage to both ever smoking and alcoholism phenotypes (Po0.01). i P-values from log-transformed smoking rate (continuous variable) and as a categorical variable (0, 1-5, 6-15, 16-25, 26-35) were provided; the more significant P-value of the two is listed here. j LOD scores were derived from both parametric and variance component methods; the highest score derived from the two methods is listed here. k Linkage is significant if P-value p0.05, and highly significant if P-value is p0.001.
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The Pharmacogenomics Journal analyses have implicated a region near DRD2 on chromosome 11q23 with cigarette consumption (Table 1) . 33 Genetic variation in DRD2 has been investigated; the TaqI A1 variant is a 32806 C4T substitution at 10 kb downstream of DRD2 and lies within a novel, as yet uncharacterized, kinase gene ANKK1. 58 Some studies, but not all, found the TaqI A1 allele resulted in a lower density of D 2 receptors in the human striatum in vitro and in vivo. [59] [60] [61] [62] The TaqI A1 allele may be a risk factor for a variety of smoking behaviors (Table 2) ; [63] [64] [65] [66] [67] [68] however, other studies were not able to replicate these findings. [69] [70] [71] [72] [73] [74] A meta-analysis did not find an association between the TaqI A1 allele and smoking initiation, smoking persistence, cigarette consumption or cessation. 75 However, these results should be interpreted carefully as significant between-study heterogeneity was observed, including differences in the phenotypes examined and the study populations.
The Taq1 B1 allele is a second RFLP that lies 913 bp upstream of the start codon in exon 2 of DRD2, suggesting that it may be a better marker for association studies of substance abuse; 65, 66, 76 it is in significant linkage disequilibrium with the Taq1 A1 allele (D 0 40.8). 77, 78 Similar to the Taq1 A1 allele, individuals with the Taq1 B1 allele were more likely to have ever smoked and started smoking at an earlier age (Table 3) . 65, 66 A 48-bp variable number tandem repeat (VNTR) in exon 3 of DRD4 has also been of interest; genome-wide linkage analyses have implicated a region on chromosome 11p15.5 near DRD4 with habitual smoking (Table 1) . 45 In African Americans, but not Caucasians, the long (L) allele (containing Table 2 Summary of studies examining TaqI A polymorphism in DRD2 and smoking behaviors Phenotype Population Association References
Smoking status Caucasians Higher frequency of the A1 allele was found among ever smokers 63, 64 No association with smoking status (ever, never) 65 No association with smoking status (current, never) 69 No association with smoking status (current smokers versus nonsmokers including former and never smokers) 70 No difference in transmission of alleles to habitual or ever smokers No association of the TaqI A polymorphism with smoking status was found in female subjects.
c Study combined African-American subjects with Mexican-American subjects because no difference in cigarette consumption was observed between the two groups.
d SCL6A3 (DAT1) nine-repeat allele was also significantly associated with increased stress and cue-induced cravings.
The genetics of cigarette smoking MK Ho and RF Tyndale 6-10 repeats) has been associated with a greater risk of current smoking, and a shorter time before the first cigarette in the morning compared to the short (S) allele (containing 2-5 repeats). 79 Individuals with the L-allele also experienced greater craving, more arousal, less positive affect and more attention to smoking cues than individuals with the S-allele. 80 In adolescents, the L-allele (seven-repeat) increased the risk of smoking and novelty seeking in males; 81 however, another study failed to replicate these findings. 82 There is modest evidence for a role of DRD1, DRD3 or DRD5 in smoking behaviors. A region near DRD1 on chromosome 5 has shown significant linkage to cigarette consumption and age of smoking initiation in genome-wide scans (Table 1) ; 32, 40, 41 one study found an association of the DdeI polymorphism in DRD1 with current smoking.
83 D 3 receptors are selectively expressed in the nucleus accumbens and they may be important in the reactivity to drugassociated stimuli. 84 Polymorphisms in DRD3 were identified that alter binding affinities and although they were implicated in cocaine addiction, 85 their relationship to smoking has not been examined. 86 There are no known variants in DRD5 occurring at frequencies greater than 1%. 87 While the microsatellite polymorphism D5 (CT/GT/GA) n located 55 kb downstream of DRD5 has been associated with substance abuse, this and four other markers close to DRD5 were not associated with smoking initiation or progression to ND. 87 However, one haplotype that did not include the D5 (CT/GT/GA) n marker had a statistically significant protective effect against smoking initiation.
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Dopamine transporter
The dopamine transporter (DAT) is a Na þ /Cl À -dependent transmembrane protein critical in the regulation of dopamine transmission. 88 A 40-bp VNTR polymorphism (3-13 repeats) has been identified in the 3 0 -untranslated region (UTR) of SCL6A3 encoding DAT1. 89, 90 The SCL6A3-9-and 10-repeat alleles occur most frequently in humans, 91, 92 but their functional impacts are unclear. 88, 93 The SLC6A3-9 allele has been associated with a lower risk of current smoking and starting smoking before age 16 years, longer periods of abstinence during previous quit attempts and increased quitting. 94, 95 However, these findings have not been replicated, 96, 97 and conversely, the SCL6A3-9 allele has also been associated with stronger cue-or stress-induced cravings. 68 Examination of a single-nucleotide polymorphism (SNP) in the 3 0 -UTR of SCL6A3-9 (rs27072G4A) found individuals with the A-allele were more likely to initiate smoking before age 18 years. 98 Dopamine metabolism TH encodes tyrosine hydroxylase, the rate-limiting enzyme for the synthesis of dopamine, and a region near this gene on chromosome 11p15.5 has been implicated with habitual smoking in genome-wide linkage scans 45 (Table 1) . 45 A fournucleotide VNTR polymorphism (HUMTH01-VNTR) in intron 1 is postulated to affect gene expression, as it resides in a region where numerous transcription factors bind. 99 Adolescent smokers with the four-repeat allele (K4) were less likely to be ND compared to those with 1-3 (K1-K3) or five repeats (K5) alleles. 100 These results were confirmed in a larger independent cohort of adolescents, and no association was found for three other putatively functional SNPs in HUMTH01-VNTR. 101 The K4 allele was not associated with smoking status (smokers versus nonsmokers) among adults, although it was associated with lower cigarette consumption. Study combined African-American subjects with Mexican-American subjects because no difference in cigarette consumption was observed between the two groups.
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Dopamine b-hydroxylase (DBH) catalyzes the conversion of dopamine to norepinephrine, and its locus on chromosome 9q34 has been implicated with cigarette consumption 40 and habitual smoking 71 in genome-wide linkage analyses (Table 1) . Polymorphisms in DBH (1368 G4A) and monoamine oxidase A (MAO-A 1460 C4T), which is also involved in dopamine metabolism, have been associated with cigarette consumption, 103 but these results were not repeated in a larger sample of the same cohort. 104 A 30-bp VNTR polymorphism in the promoter region of MAO-A has also been reported; alleles with 3.5 or four repeats were transcribed more efficiently than three or five repeats. 105 Although the four-repeat allele did not influence smoking status (current, former, never), it was associated with higher levels of ND in Japanese males. 106 Conversely, Japanese women with the four-repeat allele had a reduced risk of being a current smoker, although no association to ND was found. 106 Another study of Chinese males found those with both the four-repeat allele and 1460C allele were least likely to be current smokers. 107 In adolescents, no associations of the MAO-A VNTR polymorphisms or 1460C4T SNP were found between current, former or never smokers. 82 Catechol-O-methyltransferase is important in the degradation catecholamines, and a functional SNP (1947G4A) corresponding to Val108/158Met has been identified. Those with homozygous Val/Val genotypes have 3-4-fold higher enzyme activity compared to those with Met/Met genotypes. [108] [109] [110] The low activity Met allele appears to be protective against current smoking; Caucasian women with two Met alleles were more likely to be ex-smokers and had higher abstinence rates when randomized to either nicotine spray or transdermal patch in an open-labeled trial. 111 Further, several gender-and ethnic-specific haplotypes containing the Met allele have a protective effect against ND. 112 However, other studies have failed to find any association between the Val108/158Met variant and smoking initiation, cessation or cigarette consumption. 103, 113 Although Redden et al. 114 reported a positive association of the Val allele with levels of ND, it was not replicated in an independent sample of similar size even after controlling for covariates.
Serotonin system
Serotonin transporters Serotonin (5-HT) modulates dopamine release and has been implicated in nicotine reinforcement. 115 Serotonin levels are increased by nicotine administration and decreased during withdrawal. 116, 117 The serotonin transporter gene (5-HTT or SLC6A4) has been implicated in a number of psychiatric disorders such as depression and schizophrenia, both of which have high rates of co-morbidity with smoking. [118] [119] [120] [121] A 44-bp insertion (L-allele) or deletion (S-allele) polymorphism (5-HTTLPR) has been found in the promoter with the S-allele reducing transcription. 122 The evidence for the impact of 5-HTTLPR on smoking has been mixed; the S-allele occurred at a lower frequency in current smokers compared to former or never smokers, 123, 124 but others have not found any associations with current smoking, age of smoking initiation, cigarette consumption, Fagerstrom Tolerance Questionaire (FTQ) scores or previous quit history. 125, 126 Adolescents with the SS genotype were more likely to be current heavy smokers with earlier onset of smoking. 127 A strong relationship has been observed between the SS genotype and irritability levels, or temperament traits. Thus, the association of the 5-HTTLPR polymorphism with smoking may be partly due to the genetic influence on personality and is therefore substantially influenced by population composition. 127 This is supported by evidence that adults with the S-allele and high levels of neuroticism have greater difficulty in smoking cessation. 128 Serotonin metabolism: tryptophan hydroxylase TPH1 encodes tryptophan hydroxylase, the rate-limiting enzyme for serotonin synthesis, and it is located on chromosome 11p15.3-p14 in a region which has been implicated with habitual smoking in genome-wide linkage scans (Table 1) . 45 An SNP in intron 7 of THP1 (779 C4A) has been associated with smoking initiation, with individuals of AA genotypes reporting the earliest age. 129 The A alleles of two SNPs in strong linkage disequilibrium (779C4A, 218C4A) were found at higher frequencies among ever smokers, 130 however no association was found for the 779C4A SNP with severity of ND, quitting history and cigarette consumption. 129, 130 The AC (779C4A SNP) genotype group had higher levels of ND, as measured by the Fagerstrom Test for Nicotine Dependence (FTND), and number of cigarettes smoked per day compared to homozygous AA or CC genotypes. 131 
Cholinergic system
Cholinergic receptors
The majority of nicotine's psychoactive properties result from their binding to and activation of neuronal nicotinic cholinergic receptors (nAChRs), which are pentameric ligand-gated cation channels composed of a 2-10 and b 2-4 subunits. Animal studies have shown that receptors with a 4 and b 2 subunits comprise B90% of the high-affinity nicotine binding sites in the brain. 132 Both subunits are upregulated by chronic nicotine treatment and their absence in knockout mice results in a lack of nicotine selfadministration and nicotine-induced dopamine release in the VTA. [132] [133] [134] [135] Tapper et al. 136 genetically altered the a 4 -subunit to make it hypersensitive; low doses of nicotine that selectively activate nAChRs containing these mutated subunits produced reinforcement, tolerance and sensitization without having such effects in wild-type mice. CHRNA4 encodes the a 4 subunit, and several genetic variants have been associated with smoking. A study in Chinese men found an association of two synonymous SNPs in exon 5 (rs1044396 and rs1044397) with a lower risk of ND, 137 but these findings were not confirmed in either male or female subjects of other ethnicities. 138, 139 In an analysis of six SNPs (including rs1044396), only one (rs2236196), and its
The genetics of cigarette smoking MK Ho and RF Tyndale haplotype, was associated with protective effects against ND. 138 Evidence from knockout mice suggests the b 2 -subunit is necessary for nicotine self-administration and thus may be important in nicotine reinforcement. 134, 140 Several studies failed to find any associations between genetic variation in CHRNB2, which encodes the b 2 subunit, with smoking initiation or ND. 137, 138, 141, 142 However, Greenbaum et al.
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found that rs2072660, which had been examined in other studies with negative results, and its haplotypes had a nominally significant protective effect against smoking initiation. SNPs in CHRNA7 (rs1909884), CHRNA9 (rs4861065) and CHRNB3 (rs9298629) also appeared protective against high levels of ND (FTQ X6), although none remained significant after correction for multiple testing. 139 The prevalence of smoking among schizophrenic patients is extremely high (B80%) 143 and this may represent an attempt to self-medicate. 144 Nicotine can transiently reduce deficit of the P50-auditory evoked-potential, a physiological indicator of the illness. 145 In schizophrenics, a polymorphism in intron 2 of CHRNA7 was associated with smoking status. 146 Interestingly, the region near CHRNA7 on chromosome 15q13.1 has been associated with habitual smoking in a genome-wide linkage scan (Table 1) . 42 In a study of schizophrenic families, CHRNB2 and CHRNA2 also showed significant linkage with smoking, whereas CHRNA1 and CHRNA7 were close to significance. 147 
Other likely candidates involved in neurotransmitter systems
The g-aminobutyric acid (GABA), opiate and endocannabinoid (eCB) systems have also been implicated in nicotine addiction. Animal studies have suggested a role for the GABA B receptor in nicotine reward, 148 and the gene encoding the GABA B2 subunit is located at chromosome 9q22 in a region which has shown suggestive linkage to ND (Table 1) . 46 Significant associations were found for SNPs and haplotypes in GABAB2 with ND in both African Americans and European Americans. 149 The opiate system is important for the rewarding properties of nicotine and may be involved in drug craving. [150] [151] [152] [153] Acute nicotine administration results in release of endogenous b-endorphins 154 that activate the m-opioid receptor, and the A118G polymorphism (Asn404Asp) in OPRM1 decreases binding affinity for b-endorphins. 155, 156 OPRM1 is located in chromosome 6q24-q25 and this region was recently linked to FTND scores and withdrawal severity (Table 1) . 39 Further, high doses of the opiate antagonist naltrexone, in combination with NRT patch, increased continuous abstinence compared to NRT patch alone. 157 Some studies, although not all, have found an association between the A118G variant and opiate or alcohol addiction (reviewed by Mayer and Hollt 158 ). The eCB system has been implicated in a number of physiological functions, including substance abuse owing to its modulatory effects on the dopaminergic system in the brain. Rimonabant, the CB 1 R antagonist, has shown some efficacy in clinical trials for nicotine cessation. 159 Several studies have also found associations of (AAT) n 12-repeat polymorphisms near CNR1, encoding the CB 1 receptor, with increased cocaine dependency 160 but smoking has not been studied directly. A 365 C4A SNP in the gene encoding fatty acid amide hydrolase, the main degradative enzyme for endocannabinoids, decreases enzyme expression and activity. 161 The AA genotype group was associated with increased risk of substance abuse, however, no association was found with nicotine use when use was defined as smoking X20 cigarettes per day for X5 years. 162 A role in smoking has been proposed for genetic variations in brain-derived neurotrophic factor (BDNF), which affects dopamine and serotonin transmission. One study found an association of a haplotype in BDNF to ND in males, 163 and several studies have reported an association of BDNF to substance abuse. [164] [165] [166] Nicotine metabolism Cytochrome P450 2A6 Dependent smokers regulate the amount they smoke to maintain plasma and brain nicotine levels; 54 smoking behavior is increased when the nicotine content of cigarettes is decreased or when renal nicotine clearance is increased by urine acidification. [167] [168] [169] In vivo, B80% of nicotine is inactivated to cotinine, 170 and the highly polymorphic enzyme cytochrome P450 2A6 (CYP2A6) mediates B90% of this reaction. 171, 172 The majority of cotinine is further metabolized to trans-3-hydroxycotinine, and this reaction is mediated entirely by CYP2A6.
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CYP2A6 is located on chromosome 19 (19q13.2) and a nearby region was associated with smoking frequency (X1 cigarette per day) in a genome-wide linkage scan. 39 Large interindividual and interethnic variations in CYP2A6 activity have been reported; [170] [171] [172] [174] [175] [176] [177] this variability is mainly attributed to the large genetic variations in CYP2A6. 178, 179 A brief summary of how genetic variations in CYP2A6 affect smoking behaviors will be provided here as a detailed review was recently published. 10 Several studies have associated genetic variations leading to reduced or absent CYP2A6 activity with lower risk of smoking, 175, 180, 181 decreased cigarette consumption in adults and even in adolescents despite their low smoking rates, 175, [180] [181] [182] [183] [184] [185] [186] decreased smoking intensity, 187 shorter smoking duration, 175 decreased withdrawal symptoms during abstinence 188 and increased cessation. 189 Consistent with this, CYP2A6 inhibition in the presence of 4 mg oral nicotine resulted in higher plasma nicotine levels and reduced smoking (as indicated by decreased breath carbon monoxide levels, numbers of puffs, number of cigarettes smoked and increased latency to next cigarette) during ab libitum smoking.
190
CYP2A6 can also bioactivate several procarcinogens including 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK), one of the most potent and abundant procarcinogens
The genetics of cigarette smoking MK Ho and RF Tyndale found in tobacco smoke. 191, 192 Inhibition of CYP2A6 activity in smokers increased clearance of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) glucuronide metabolite, suggesting a decreased metabolic activation of NNK and a shunting of NNK to detoxifying NNAL pathways. 193 The loss-of-function allele (CYP2A6*4) has been associated with a decreased risk of smoking-related cancers, 184, [194] [195] [196] whereas enhanced CYP2A6 activity, such as the duplication allele (CYP2A6*1X2), is predicted to increase risk.
Some studies have failed to find any association between CYP2A6 genetic variations and cigarette consumption, smoking status or lung cancer. 195, [197] [198] [199] [200] One meta-analysis failed to find any association between CYP2A6 genotypes to smoking status or cigarette consumption, 201 although another found a modest effect of CYP2A6 on smoking cessation and cigarette consumption. 202 This may be owing to several factors, such as lack of statistical power, population stratification, different genotyping assays, the presence of many unidentified and uncharacterized CYP2A6 alleles (http://www.imm.ki.se/CYPalleles/cyp2a6.htm) among individuals designated as wild type and variations in definitions of smoking phenotypes/groups. In a study restricted to Caucasian smokers (X100 cigarettes/lifetime) and nonsmokers (o100 cigarettes/lifetime), slow inactivators had a lower risk of being a current smoker regardless of whether they were DSM-IV dependent. 175 Slow inactivators also smoked less cigarettes per day, had earlier ages of smoking initiation and trended towards smoking for a shorter duration, although these were observed among dependent smokers only. 175 This illustrates how smokers are not a homogenous group and a failure to account for differences among smoking phenotypes (such as the presence of ND) may confound results. Thus, such factors should be taken into consideration in the design and interpretation of candidate gene association studies.
Limitations in genetic studies of smoking
There are several major limitations common to both genome-wide linkage analyses and candidate gene association studies. Non-replication of results is common among studies for complex behavioral traits such as smoking, as there are many variables that may, or may not, have been controlled for. Different methodology (e.g. prospective versus retrospective, method of recruitment such as population-based versus clinic-based) may result in study populations with different demographics. 203 Inclusion of subjects from various ethnic backgrounds could result in population stratification and confound results, as allele frequencies and cultural views of smoking may differ between ethnicities. 203, 204 Further, examination of genetic variants without a demonstrated functional impact may decrease the chance of replication as these markers may be linked with causal variants in some populations but not others.
There is also a lack of agreement between definitions of phenotypes, particularly with the categorical variable of smoking status. In some cases, it is unclear whether nonsmokers included ex-smokers or whether ever-smokers included light smokers. Further, these categories do not account for variations in smoking intensity, duration or dependence. The phenotype of ND is complicated by the numerous definitions available including direct measures (FTND, FTQ, Diagnostic and Statistical Manual of Mental Disorders -IV (DSM-IV), International Classification of Diseases -10 (ICD-10)) and indirect proxy measures (selfreported cigarette consumption, age of smoking initiation). Particularly in certain subpopulations, such as adolescents or light smokers, ND may be difficult to measure reliably. The use of smoking endophenotypes that can be accurately recorded in a laboratory setting may resolve some of the problems of broad phenotypes and increase statistical power to detect gene associations. 80 Examples of these include cueelicited cravings, abstinence induced withdrawals and initial sensitivity to nicotine. 80, 204 Given the polygenetic nature underlying smoking behaviors, with each gene having a moderate role, the lack of robust genetic associations is not entirely unexpected. 204 
Genetic basis for variations in response to smoking cessation treatments
Approximately 70-80% of smokers relapse by 12 months following drug treatment; 7 thus, genetic information can potentially be used to personalize drug treatments for smoking cessation to increase their efficacy. Candidate gene association studies have implicated several genetic variants in altering rates of smoking cessation; however, clinical trials with appropriate controls can provide more convincing evidence. NRTs are thought to work by preventing withdrawal symptoms, thus decreasing the negative reinforcement of smoking 205 while Zyban (bupropion) likely works by inhibiting the reuptake of norepinephrine and dopamine and as a noncompetitive antagonist at nAChRs. [206] [207] [208] A brief overview of how pharmacogenetics can improve smoking cessation outcomes will be covered here; more detailed discussions can be found elsewhere. 209, 210 Much attention has focused on genetic variations in the dopamine pathway, particularly DRD2. A study of heavy smokers (X15 cigs/day) randomized to transdermal nicotine patch or placebo found those with at least one Taq1 A1 allele were more likely to quit on the patch at the end of treatment (EOT) and 12 weeks follow-up, especially if the G allele of the DBH 1368G4A SNP was also present. 211 Subsequent analyses of this cohort found the TaqI A1 allele was associated with higher abstinence rates in women but not men at all time points examined (EOT, 12, 24 and 52 months, 8 years). 212 Conversely, women with the TaqI A1 genotypes appear to do worse on bupropion, reporting more side effects and relapse at 12 months follow-up. 213, 214 There is evidence the À141C Ins/Del variant in DRD2, which has been associated with increased transcriptional activity in vitro, 215 is predictive of outcomes to NRT or bupropion. Subjects homozygous for the À141C Ins allele
The genetics of cigarette smoking MK Ho and RF Tyndale had higher abstinence rates on bupropion (35%) versus placebo (19%), whereas those with the À141C Del allele responded better to nicotine nasal spray (42%) and transdermal patch (50%) compared to placebo (33%) or bupropion (20%) at EOT. 216 It has been proposed that genotypes resulting in lower expression of D 2 receptors (TaqI A1 or -141C Del alleles) respond better to NRT, 211, 216 whereas those with higher expression (TaqI A2 or À141C Ins alleles) respond better to bupropion. 214, 216 Bupropion may be a better replacement for the subjective effects of smoking compared to NRT in subjects with higher levels of D 2 receptors assuming that its effect is partly mediated by its inhibition of dopamine reuptake and enhancement of dopamine levels. 216 Other important candidate genes that have been studied include those encoding 5-HT transporters and m-opioid receptors. Munafo et al. 217 found no association between 5-HTTLPR and abstinence following nicotine patch, spray or combination therapy by EOT or at 6 months follow-up. However, the study did not include a placebo arm, so it is unclear whether 5-HTTLPR polymorphisms affect cessation compared to those without pharmacological treatment. There is evidence that the Asn40Asp variant in OPRM1 influences the efficacy of NRTs. In a clinical trial where subjects were randomized to either transdermal nicotine patch or nasal spray, those with the Asp40 variant were more likely to be abstinent, and reported less weight gain and mood disturbances, compared to subjects homozygous for Asn40. 218 This effect was mainly observed in the nicotine patch group. 218 Bupropion is primarily metabolized to the active metabolite hydroxybupropion, and this is mostly mediated by CYP2B6 in vitro. 219, 220 Lerman et al. 221 examined the 1459C4T SNP (R487C), which decreases enzyme expression, 221, 222 and reported subjects with at least one T allele were more likely to relapse and had higher cravings at EOT. 221 However, there was a significant genotype Â gender Â treatment interaction where women with the T allele had similar abstinence rate on bupropion, but did worse on placebo compared to those without the T allele. 221, 223 There is evidence suggesting CYP2B6 is also expressed in the brain and can potentially metabolize nicotine. [224] [225] [226] As such, genetic variations in CYP2B6 may represent additional differences in sensitivity to nicotine with consequent effects on smoking cessation.
Subjects with genetic variants in CYP2A6 are hypothesized to respond differently to NRTs owing to their lower rates of nicotine metabolism. CYP2A6 slow metabolizers have higher nicotine plasma levels while on the transdermal nicotine patch compared to normal metabolizers, whereas slow metabolizers on nicotine spray achieved nicotine levels similar to that of normal metabolizers through reducing the number of nicotine sprays used per day. 183 Using the 3HC/ COT ratio, an indicator of CYP2A6 activity, slow metabolizers have higher nicotine levels and increased efficacy on the transdermal patch, but not while using nasal spray. 227 Slow CYP2A6 activity may be more important in therapeutic outcomes for NRT forms where dosages are constant (e.g. transdermal patch), compared to those where dosages can be adjusted for differing rates of metabolism and need (e.g. nasal spray).
Conclusions
Despite the obvious health hazards associated with cigarette smoking, a substantial number of people are currently smokers. Of great additional concern is the rising prevalence of smoking in developing countries. 228 One focus of research has been the genetic influences on the etiology of cigarette smoking. Understanding the genetic underpinnings of smoking behaviors should: (1) enable us to understand the mechanisms involved in the development of ND and smoking cessation, (2) allow us to optimize currently available treatments and (3) provide us with biologically relevant targets for the development of novel pharmacotherapies.
